Alzheimer’s disease

Studying spinal fluid from people at risk for Alzheimer’s disease, School of Medicine researchers have found that a gene variation that had not been considered risky actually can increase the chances of developing Alzheimer’s disease when it occurs in tandem with another gene variant known to elevate risk. Shown is an image of a brain with a buildup of amyloid deposits (highest amounts in yellow and red) that collect to form senile plaques in patients with Alzheimer’s.

Finding ways to diagnose and treat Alzheimer’s disease has frustrated scientists and clinicians for decades. But now the battle has reached a potentially significant milestone: the launch of the first clinical trials to test whether giving new drug treatments before dementia can prevent Alzheimer’s. Shown are School of Medicine MDs and Alzheimer’s researchers Randall Bateman (left) and John C. Morris.

School of Medicine scientists have found a way that corrupted, disease-causing proteins spread in the brain, potentially contributing to Alzheimer’s disease, Parkinson’s disease and other brain-damaging disorders. Pictured are clumps of corrupted tau protein outside a nerve cell, as seen through an electron micrograph.

In patients with early Alzheimer’s disease, disruptions in brain networks emerge about the same time as chemical markers of the disease appear in the spinal fluid, School of Medicine researchers have shown. Pictured is senior author of the study, Beau Ances, MD, PhD, associate professor of neurology and of biomedical engineering.

Scientists at the School of Medicine have measured a significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer’s disease and healthy family members who do not carry the mutation. Randall Bateman, MD, is the study’s senior author.

XPRIZE may create an Alzheimer’s XPRIZE to inspire the ingenuity of researchers to take on the daunting task of stopping the disorder. The Alzheimer’s XPRIZE was proposed by a team of experts co-directed by Eric C. Leuthardt.

School of Medicine researchers have shown that several markers for presymptomatic Alzheimer’s disease identified in recent years are accurate predictors of Alzheimer’s years before symptoms develop. Catherine Roe, PhD, says researchers found no differences in the accuracy of the biomarkers.

Memory problems related to day-to-day activities — one of the largest complaints of people with Alzheimer’s diease — may be due to older adults’ inability to segment their daily lives into discrete experiences, suggests new psychology research from Washington University in St. Louis. How we perceive events in our current lives influences how we remember them in the future, the study finds.

Scientists’ picture of how a gene strongly linked to Alzheimer’s disease harms the brain may have to be revised, researchers at the School of Medicine have found. Washington University’s David M. Holtzman, MD, says leading researchers recently agreed that targeting this gene is a promising approach for gaining a better understanding of and improving treatments for the disease.

Researchers at Washington University have identified a new set of genetic markers for Alzheimer’s disease that point to a second pathway through which the disease develops. Much of the genetic research in Alzheimer’s centers on amyloid-beta, a key component of brain plaques in people with the disease. But the new study identified several genes linked to the tau protein, which is found in tangles.